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Dear Editor, 
Acenocoumarol, is a racemic mixture of the optical R (+) and S (-) enantiomers. R (+) 
enantiomer is several times more potent than the S (-) enantiomer (Godbillon et al., 1981). 
Acenocoumarol is rapidly absorbed following oral absorption with approximately 60 % of the 
dose available systemically (Trailokya, 2015). After a single dose of 10 mg, the peak plasma 
concentrations (Cmax) of acenocoumarol are reached within 1-3 h and the area under the plasma 
concentration-time curve (AUC) values are proportional to the dose in the dosage range of 8 to 
16 mg (Sasso et al., 2012). The protein binding of acenocoumarol is 98 % (Trailokya et al., 
2016). Acenocoumarol is mainly metabolized by CYP2C9 (Trailokya, 2015); 6- and 7-hydrox-
ylation of both enantiomers of acenocoumarol are the major metabolites (Thijssen et al., 2000). 
The elimination half-life of acenocoumarol is 8 to 11 h (Sánchez et al., 2013). Approximately, 
29 % of acenocoumarol excrete in feces and 60 % in urine. The starting dose of acenocoumarol 
usually ranged from 2 to 4 mg. Based on the prothrombin time, subsequent loading doses may 
be recommended (Trailokya, 2015). 
Acenocoumarol is reported to exhibit a dose-proportional pharmacokinetics for the 8 to 16 
mg doses (Trailokya, 2015). However, no information is available for the dose-proportionality 
of lower doses of acenocoumarol (i.e. 1 to 4 mg doses). We aimed to evaluate the dose-propor-
tionality of acenocoumarol by performing a literature search and plotting a linear curve for 
AUC vs. dose from the available information. 
Literature related to pharmacokinetics of acenocoumarol was searched in PubMed. A total 
of 115 from 1618 articles were identified related to acenocoumarol’s pharmacokinetics. From, 
115 articles, 9 articles were identified as potentially relevant, as these articles reported the AUC 
values at different time points such as 24, 48, 72 h and at infinite time. These articles were 
finally considered for the evaluation of linearity of acenocoumarol pharmacokinetics. Various 
studies have reported the AUC0-48 and AUC0-∞ values of acenocoumarol for 1, 4, 10 and 12 mg 
dose (Table 1). No other information on AUC0-48 and AUC0-∞ were available with the 2, 8 and 
16 mg dose. The pharmacokinetics data across these studies were used to generate a dose-
proportionality curve (acenocoumarol dose vs. AUC0-48 or acenocoumarol dose vs. AUC0-∞). 
The dose-proportionality curves between AUC and acenocoumarol doses (AUC0-48 vs. dose, 
and AUC0-∞ vs. dose) are presented in Figure 1.  
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An R2 of 1 indicates that the regression predictions perfectly fit the data. Therefore, from 
the value of R2 (0.9988 for AUC0-48 vs. dose, and 0.9874 for AUC0-∞ vs. dose), it is clear that 
acenocoumarol exhibits a dose-proportional pharmacokinetics. 
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Table 1: AUC0-48 and AUC0-∞ values of acenocoumarol from literature search 
Dose 
(mg) Subject (n) 
AUC 
Reference 0-24 0-48 0-72  0-∞ 
R-AC S-AC R-AC S-AC R-AC S-AC R-AC S-AC 
1 28 - - 107 - - - 126 - 
Public Assessment Re-
port, Acenocoumarol, 
2013 
4 24 1364.38 - - - - - 1786  - Sasso et al., 2012 
10 12 - - 3315 289 - - 3807 361 Rolan et al., 2003 
10 18 - - - - 2529 169 - - Huang et al., 2008 
10 12 - - - - 3831  382.4 3962 387.3 Sunkara et al., 2004 
10 6 - - 3458 479 - - - - Masche et al., 1999 
10 7 - - 3400 - - - - - Thijssen and Hamulyàk, 1989 
10 5 - - - - - - 3900 - Thijssen and Baars, 1983 
12 8 - - 3866.36 - - - - - Popovic et al., 1994 
Abbreviation denotes – AUC: area under the plasma concentration curve; R-AC: (R)-enantiomer of acenocoumarol; S-AC: (S)-enantiomer of acenocoumarol 
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Figure 1: Dose-proportionality curves between AUC and acenocoumarol doses (AUC0-48 vs. dose, and 
AUC0-∞ vs. dose) 
 
 
 
 
 
